Quantcast

FDA issues three warning letters to companies dealing with cannabis related products

In a statement from the US FDA commissioner, the FDA on Tuesday said it has issued warning letters, in collaboration with the Federal Trade Commission, to three companies – Advanced Spine and Pain LLC (d/b/a Relievus), Nutra Pure LLC and PotNetwork Holdings Inc. – in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.

Read more

Molecular Partners, Allergan to file abicipar BLA in USA in the first half of 2019

Allergan and Molecular Partners revealed Tuesday the topline safety results from MAPLE, study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process, which showed lower incidence and type of IOI.

Read more

Trovagene expects additional evidence of clinical efficacy of onvansertib combined with chemoterapy in Acute Myeloid Leukemia

Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.

Read more